Sanofi plans share buyback as profits fall

Faltering products and pipeline problems have beset Sanofi-Aventis. Analysts were disappointed as net profits declined about 6%, falling from 1.79 billion euros to 1.68 last quarter. Sales of Ambien/Stilnox and Eloxatin fell thanks to new generic competition. An FDA advisory panel’s thumbs down on Zimulti/Acomplia also hurt. One bit of good news was a rebound in Plavix sales following a skirmish with a generic rival. The company says it will buy back up to 3 billion euros ($4.1 billion) worth of stock by May 2008

- see the Sanofi release

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.